Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 3/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16033404 | 0.72 | KDM2B (0.64) | KDM2BKDM5AKDM4CKDM5B | |
| SCHEMBL17710646 | 0.72 | KDM2B (0.41) | KDM2BKDM5AKDM4CKDM5B | |
| SCHEMBL19101734 | 0.69 | KDM2B (0.41) | KDM2BPRMT5WDR77KDM5AKDM4C | |
| SCHEMBL6206540 | 0.62 | CRHBP (0.41) | — | |
| SCHEMBL16238565 | 0.61 | LMNA (0.36) | KDM4C | |
| SCHEMBL29520117 | 0.61 | LMNA (0.36) | KDM4C | |
| SCHEMBL16033410 | 0.58 | KDM2B (0.74) | KDM2BKDM5AKDM4CKDM5B | |
| SCHEMBL3451078 | 0.57 | AKR1C1 (0.36) | — | |
| SCHEMBL5242137 | 0.56 | DRD3 (0.44) | DRD2ACACB | |
| SCHEMBL19101737 | 0.56 | KDM2B (0.40) | KDM2BPRMT5WDR77KDM5AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527829-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160122314-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122314-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | S1PR1 3095/4885S1PR3 3219/4885NAMPT 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.